uniQure: Further Upside Likely As The Opportunity Becomes Better Understood
2025-10-08 15:33:48 ET
uniQure’s ( QURE ) stock skyrocketed in late September after the announcement of stronger-than-expected Huntington’s trial data. Despite a more than 300% increase in the share price, the market still seems to be undervaluing uniQure, which likely stems from uncertainty around the validity of the trial data (small number of patients, relied on an external control arm). The strength of the data across endpoints, the design of uniQure’s therapy, and the use of a localized delivery mechanism are supportive of efficacy, though. Based on the strength of the data, AMT-130 is likely to receive an accelerated approval and reach the market sometime in the next year or so....
Read the full article on Seeking Alpha
For further details see:
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood
NASDAQ: QURE
QURE Trading
12.32% G/L:
$28.18 Last:
1,923,430 Volume:
$28.61 Open:
